治疗动脉样硬化的低剂量胆固醇:长期安全性
Stefan Mark Nidorf1, Eldad Ben-Chetrit2, Paul M Ridker3
1Heart and Vascular Research Institute, Harry Perkins Institute of Medical Research, 3/140 Mounts Bay Rd, Perth, Western Australia 6000.
在冠状动脉疾病患者长期使用低剂量胆固醇是安全的,副作用最小,如暂时腹. 这种药物耐受性很好,不会增加主要健康问题的风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 低剂量胆固醇 (每天0.5毫克) 是FDA批准用于冠心病患者的二次预防.
- 越来越多的临床使用需要了解持续低剂量菌素的安全性.
研究的目的:
- 为了告知医生,药剂师和患者持续使用低剂量菌素的绝对风险.
- 评估安全性,包括在接受他类药物治疗的患者中.
主要方法:
- 从病例报告的系统审查,药物注册表和安慰剂对照试验中收集的数据.
- 专注于与各种临床环境中连续使用菌素相关的安全问题.
主要成果:
- 连续低剂量胆固醇是耐受性良好和安全的,轻度腹是主要的短暂副作用.
- 没有对脏,肝脏或认知功能,出血,伤口愈合,生育能力或怀孕的不良影响.
- 没有增加癌症,严重感染或因特定原因死亡的风险;罕见的骨髓抑制/肌毒性/药物相互作用,类似于安慰剂.
结论:
- 连续低剂量粉素在没有显著脏或肝功能障碍的患者中安全降低心血管风险.
- 为医疗保健提供者和患者提供有关安全性概况的保证,即使是与他类药物联合治疗.
更多相关视频
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
10:28Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
